BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanda T, Matsuoka S, Moriyama M. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt. Hepatol Int 2018;12:291-3. [PMID: 29992512 DOI: 10.1007/s12072-018-9883-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Saif-Al-Islam M, Abdelaal UM, Younis MA, Alghany Algahlan HA, Khalaf S. Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. Gastroenterol Res Pract 2021;2021:8811203. [PMID: 34122539 DOI: 10.1155/2021/8811203] [Reference Citation Analysis]
2 Totsuka M, Honda M, Kanda T, Ishii T, Matsumoto N, Yamana Y, Kaneko T, Mizutani T, Takahashi H, Kumagawa M, Sasaki R, Masuzaki R, Kanezawa S, Nirei K, Yamagami H, Matsuoka S, Ohnishi H, Okamoto H, Moriyama M. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. Intern Med 2021;60:2061-6. [PMID: 33518580 DOI: 10.2169/internalmedicine.6728-20] [Reference Citation Analysis]
3 Amer F, Yousif MM, Hammad NM, Garcia-Cehic D, Gregori J, Rando-Segura A, Nieto-Aponte L, Esteban JI, Rodriguez-Frias F, Quer J. Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment. Infect Drug Resist 2019;12:2799-807. [PMID: 31571936 DOI: 10.2147/IDR.S214735] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Abdel Fattah NK, Shaheen SM, Ahmed OA, Elsaeed K, Sabri NA. Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals. F1000Res 2022;11:649. [DOI: 10.12688/f1000research.109397.1] [Reference Citation Analysis]